Cleopatra breast cancer study
WebNov 20, 2014 · Through comprehensive prospective analyses, CLEOPATRA biomarker data demonstrate that HER2 is the only marker suited for patient selection for the trastuzumab … WebApr 23, 2024 · “This end-of-study analysis of CLEOPATRA showed that the overall survival improvement with first-line pertuzumab, trastuzumab, and docetaxel versus placebo, …
Cleopatra breast cancer study
Did you know?
WebSep 13, 2024 · Purpose In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzumab plus trastuzumab and docetaxel vs. placebo that was seen in the … WebMar 18, 2024 · medwireNews: Long-term results from the CLEOPATRA trial show that the addition of pertuzumab to trastuzumab and docetaxel provides a significant and durable …
WebDec 16, 2011 · Trastuzumab, pertuzumab, and docetaxel: CLEOPATRA. Use of trastuzumab and pertuzumab—anti-HER2 monoclonal antibodies—with docetaxel as a … WebOct 16, 2013 · Study design and treatment. Study details have been published previously [18, 19].CLEOPATRA was a randomized, double-blind, placebo-controlled phase III trial designed with two treatment arms: placebo, trastuzumab (Herceptin ®, F. Hoffmann-La Roche, Basel, Switzerland) and docetaxel (Taxotere ®, Sanofi-Aventis, Paris, France) …
WebTHE CLEOPATRA BREAST CANCER TRIAL TRANSLATING RESEARCH INTO PRACTICE ... crued to the study from February 2008 to May 2010; 406 were randomly assigned to the control group WebBackground CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in …
WebHER2-positive metastatic breast cancer in the Clinical Evaluation of Pertuzumab and Tras-tuzumab (CLEOPATRA) trial. Analysis of the pri - mary end point showed that patients …
WebPhase Ib study in Japanese patients. A multicenter, single-arm, Phase Ib study (JO22992) using a combination of T-DM1 and pertuzumab was performed in Japanese patients with HER2-positive metastatic breast cancer who had received prior treatment with trastuzumab and chemotherapy. 16 Six patients received T-DM1 3.6 mg/kg with pertuzumab (a 840 … marriage in the ussrWebDec 5, 2024 · We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after... marriage in the woodsWebMay 1, 2024 · Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results … marriage in the newsmarriage in the worldWebThe Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study assessed the efficacy and safety of pertuzumab plus trastuzumab … marriage in things fall apartWebDec 15, 2012 · Abstract. Background: In CLEOPATRA, 808 pts with HER2-positive 1L MBC were randomized to treatment with placebo (Pla)+T+D or P+T+D. The primary endpoint of independently reviewed progression-free survival was significantly improved with P+T+D vs Pla+T+D (HR = 0.62; P<0.0001; medians, 18.5 vs 12.4 mths) (Baselga et al. NEJM … nbc today steals \\u0026 dealsWebJan 13, 2024 · Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, … nbc today streaming